These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 1826479

  • 1. Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci.
    Kenny MT, Dulworth JK, Brackman MA.
    Diagn Microbiol Infect Dis; 1991; 14(1):29-31. PubMed ID: 1826479
    [Abstract] [Full Text] [Related]

  • 2. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC, Ribou G, Masquelier B.
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT, Schønheyder H, Pers C, Thomsen VF.
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [Abstract] [Full Text] [Related]

  • 4. Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States.
    Jones RN, Goldstein FW, Zhou XY.
    Antimicrob Agents Chemother; 1991 Mar; 35(3):584-6. PubMed ID: 1828137
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of the new glycopeptide decaplanin.
    Neu HC, Chin NX, Niu WW.
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
    [Abstract] [Full Text] [Related]

  • 6. [The invitro activity of teicoplanin and vancomycin against gram positive microorganisms (corrected)].
    Kayaokay Y, Hasçelik G, Gür D, Akalin E.
    Mikrobiyol Bul; 1991 Oct; 25(4):321-5. PubMed ID: 1839050
    [Abstract] [Full Text] [Related]

  • 7. Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.
    Low DE, McGeer A, Poon R.
    Antimicrob Agents Chemother; 1989 Apr; 33(4):585-8. PubMed ID: 2543286
    [Abstract] [Full Text] [Related]

  • 8. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL, Jack-Wait K, Wannamaker N, Walden TP, Gilligan PH.
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [Abstract] [Full Text] [Related]

  • 9. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
    Felmingham D, Brown DF, Soussy CJ.
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
    [Abstract] [Full Text] [Related]

  • 10. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers.
    Jones RN, Barry AL, Gardiner RV, Packer RR.
    Diagn Microbiol Infect Dis; 1989 Aug; 12(5):385-94. PubMed ID: 2533050
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci.
    Mini E, Novelli A, Mazzei T, Periti P.
    Eur J Clin Microbiol Infect Dis; 1989 Mar; 8(3):256-60. PubMed ID: 2523807
    [Abstract] [Full Text] [Related]

  • 12. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
    Fajardo Olivares M, Hidalgo Orozco R, Rodríguez Garrido S, Gaona Álvarez C, Sánchez Silos RM, Hernández Rastrollo R, Martínez Tallo E, Cordero Carrasco JL.
    Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer.
    Rolston KV, Nguyen H, Messer M.
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2137-41. PubMed ID: 2149921
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
    Shonekan D, Mildvan D, Handwerger S.
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides.
    Del' Alamo L, Cereda RF, Tosin I, Miranda EA, Sader HS.
    Diagn Microbiol Infect Dis; 1999 Jul; 34(3):185-91. PubMed ID: 10403098
    [Abstract] [Full Text] [Related]

  • 16. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A, Debbia EA, Bacca D, Balistreri G, Musolino B, Schito GC.
    Drugs; 1997 Jul; 54 Suppl 6():11-20. PubMed ID: 9474477
    [Abstract] [Full Text] [Related]

  • 17. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
    Bartoloni A, Colao MG, Orsi A, Dei R, Giganti E, Parenti F.
    J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.
    Gorzynski EA, Amsterdam D, Beam TR, Rotstein C.
    Antimicrob Agents Chemother; 1989 Nov; 33(11):2019-22. PubMed ID: 2532875
    [Abstract] [Full Text] [Related]

  • 19. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.
    Lawrence T, Rotstein C, Beam TR, Gorzynski EA, Amsterdam D.
    Antimicrob Agents Chemother; 1993 Apr; 37(4):896-900. PubMed ID: 8494388
    [Abstract] [Full Text] [Related]

  • 20. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
    Grüneberg RN, Hryniewicz W.
    Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.